Fractyl ais a biotechnology company looking to bring curative therapies to the large populations of patients with metabolic disease.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/16/2021 | Series F | $100MM | $xx.xx | $872.9MM | Maverick Capital, M28 Capital, Population Health Partners | |
Price per Share
$xx.xx
Shares Outstanding
11,927,048
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Maverick Capital, M28 Capital, Population Health Partners
|
||||||
08/06/2020 | Series E | $55.07MM | $xx.xx | $378.52MM | Taiwania Capital Management Corporation, Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, Google Ventures, Catalio Capital Management, CDIB Venture Capital, YJ Capital | |
Price per Share
$xx.xx
Shares Outstanding
12,838,573
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Taiwania Capital Management Corporation, Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, Google Ventures, Catalio Capital Management, CDIB Venture Capital, YJ Capital
|
||||||
11/30/2017 | Series D | $43.98MM | $xx.xx | $260.81MM | Google Ventures, True Ventures, IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, Deerfield Management Company | |
Price per Share
$xx.xx
Shares Outstanding
11,994,461
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Google Ventures, True Ventures, IDO Fund, General Catalyst, Bessemer Venture Partners, Domain Associates, Mithril Capital Management, Emergent Medical Partners, Deerfield Management Company
|
||||||
11/19/2015 | Series C-2 | $47.17MM | $xx.xx | $169.58MM | Deerfield Management Company, Mithril, General Catalyst, Bessemer Venture Partners, Domain Associates | |
Price per Share
$xx.xx
Shares Outstanding
15,336,464
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Deerfield Management Company, Mithril, General Catalyst, Bessemer Venture Partners, Domain Associates
|
||||||
11/19/2015 | Series C-1 | $20.26MM | $xx.xx | $169.58MM | Deerfield Management Company, Mithril, General Catalyst, Bessemer Venture Partners, Domain Associates | |
Price per Share
$xx.xx
Shares Outstanding
9,064,640
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Deerfield Management Company, Mithril, General Catalyst, Bessemer Venture Partners, Domain Associates
|
||||||
03/21/2013 | Series B | $14.5MM | $xx.xx | $28.61MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
11,451,453
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|
||||||
06/15/2011 | Series A | $5.5MM | $xx.xx | $11MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
5,500,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed Investors
|